2Nakamura M, Fujiakra H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in JAPAN: results of a multicenter registry in Japanese Society of Pulmonery Embolism Research. Clin Cardiol, 2001,24: 132-138.
3Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombelytic treatment and the prognosis of hemodynamically stable patients with magor pulmonary embolism: results of a multicenter registry. Circulation, 1997,96: 882-888.
5Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clnicl trial of streptokinase and heparin in treatment of life threatening pulmonary embolisml. Br Med J, 1974,1:343-347.
6Ly B, Amesen H, Eie H, et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolisml. Acta Med Scand, 1978,203: 465-470.
7Marini C, Di-Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparan in acute pulmonary embolism: a randomized clinical trial. Respiration, 1988,54:162-173.
8PTOPEI. Tissue plasminogen activator for the treatment of acutepulmonary embolism: a colladorative study by the PIOPED inestigators. Chest, 1990,97 : 528-533.
9Levine M, Hirsh J, Weitz J, et al. A randomized teial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990,98:1473-1479.
10Hnadler JA, Feied CF. Acute pulmonary embolism. Aggressire therapy with anticoagulants and thrornolytics. Postgrad Med, 1995,97:61-72.
